Vision is a complex mechanism that limits the ability of technology to replace its natural functions such as interpreting, gathering and focusing on images. However, advances in technology in this steadily evolving field are providing solutions including techniques and procedures to improve human vision.
Learn more about what is happening in the field of vision care:
ZEISS Medical Technology and Boehringer Ingelheim announces a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases. The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms and the development of first-in-class treatments to detect early and treat retinal diseases before irreversible vision loss occurs.
More than 300 million people worldwide are at risk today of losing their eyesight due to diseases leading to functional loss of the retina. The number of people suffering from vision loss is rising due to aging populations and widening health inequity gaps. Undiagnosed and untreated retinal diseases have a profound impact on people’s lives, potentially leading to isolation, loss of independence, depression and reduced quality of life. Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all.
Source: ZEISS
The best complete lens portfolio by Zeiss is an innovative modern product offering to cater to the visual needs of today’s consumers, no matter their age.
We live in a digital community and being connected is the new normal. With digital devices being an integral part of our lives we have access to more people, information and things.
In response to relevant consumer insights and extensive research on modern visual behavior, Zeiss has developed a new lens portfolio to help all eyeglass wearers keep up with the times. The first of its kind, the Zeiss SmartLife Lens portfolio is a complete, all-day lens offering to address the everyday visual needs of modern consumers, throughout their lives.
The U.S. Food and Drug Administration recently approved the first contact lens to slow the progression of myopia (nearsightedness) as an initial treatment for children ages 8-12.
Cooper Vision's MiSight contact lens is a single-use, disposable, soft contact lens not intended to be worn overnight.
Until now, traditional eyeglasses and contact lenses available in the U.S. have only been developed to correct blurred vision, a symptom of myopia, and not approved to slow its progression.
Allergy season can make your eyes itchy and red, and relief often comes in the form of eye drops. What if contact lenses were preloaded with an antihistamine to help reduce that itchiness caused by allergies?
Researchers at Johnson & Johnson Vision Care say single-use contact lenses that dispense the antihistamine ketotifen showed promising results in two Phase 3 clinical trials. Results of the study were published in the journal Cornea in March.
Lead investigator Brian Pall, director of clinical science at Johnson & Johnson Vision Care, says antihistamine-dispensing lenses "look promising in their ability to reduce eye itch".
Why put antihistamines in contacts? "Eye drops are contraindicated for contact lens wearers," Pall says. The itchiness caused by allergies leads the contact lens wearer to rub his or her eyes, possibly damaging the lenses.
Contact lens wearers now must take out their contacts, apply eye drops and then switch to glasses until the antihistamine takes effect.
Some eyeglass lenses darken automatically in sunlight to reduce glare and help you see more comfortably in bright light. Now the same photochromic technology is available in Acuvue Oasys contact lenses.
Acuvue parent company Johnson & Johnson Vision and Transitions Optical have teamed up to produce the first light-adaptive contact lenses. The collaboration between the two teams of researchers began about a decade ago.
"We had to overcome a huge technology hurdle to make this happen," David Turner, head of contact lens research and development at Johnson & Johnson Vision, told Time magazine. Acuvue Oasys with Transitions was named one of Time's "Best Inventions of 2018."
The two-week disposable lenses also block the sun's harmful UV rays and prevent potentially damaging blue light from entering the eye.
We'll keep you updated on more information on this innovative development.
For better web experience, please use the website in portrait mode
Welcome to Rivoli Group! To enhance your experience, this website utilizes cookies. These cookies help us make our website and services more user-friendly and meaningful for you. Additionally, they allow us to gain insights into how our customers use our platforms. By using our website and services, you agree to our Privacy Statement. To learn more about how we handle your data, please read our Privacy Policy. Read More
